Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last 4,181 INR
Change Today +50.65 / 1.23%
Volume 303.6K
DRRD On Other Exchanges
Symbol
Exchange
Natl India
Mexico
Frankfurt
As of 7:05 AM 08/28/15 All times are local (Market data is delayed by at least 15 minutes).

dr. reddy's laboratories (DRRD) Snapshot

Open
4,230
Previous Close
4,130
Day High
4,239
Day Low
4,159
52 Week High
08/14/15 - 4,338
52 Week Low
10/17/14 - 2,867
Market Cap
712.8B
Average Volume 10 Days
481.2K
EPS TTM
137.18
Shares Outstanding
170.5M
EX-Date
07/10/15
P/E TM
30.5x
Dividend
20.00
Dividend Yield
0.48%
Current Stock Chart for DR. REDDY'S LABORATORIES (DRRD)

Related News

No related news articles were found.

dr. reddy's laboratories (DRRD) Related Businessweek News

No Related Businessweek News Found

dr. reddy's laboratories (DRRD) Details

Dr. Reddy’s Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment produces and markets finished pharmaceutical products as branded formulations or generic finished dosages. This segment also engages in biologics business. The PSAI segment develops active pharmaceutical ingredients (APIs) and intermediaries, which are used as principal ingredients for finished pharmaceutical products. This segment also offers contract research services to other companies; and manufactures and sells APIs and steroids in accordance with the specific customer requirements. The Proprietary Products segment focuses on the discovery, development, and commercialization of novel small molecule agents in therapeutic areas, such as anti-infective, metabolic disorders, and pain and inflammation. It also provides differentiated formulations for unmet medical needs; and a portfolio of in-licensed patented dermatology products As of March 31, 2015, this segment had 18 active products in proprietary products development pipeline that are in various stages of development. The company’s therapeutic categories primarily include gastro-intestinal, cardiovascular, pain management, oncology, dermatology, urology, and nephrology. Dr. Reddy’s Laboratories Limited has strategic partnership with GlaxoSmithKline plc to develop and market products outside India; collaboration, license and option agreement with Curis, Inc. to discover, develop, and commercialize small molecule antagonists for immuno-oncology and precision oncology; and collaboration agreement with Merck Serono to develop a portfolio of biosimilar compounds in oncology, primarily focused on monoclonal antibodies. The company was founded in 1984 and is headquartered in Hyderabad, India.

20,373 Employees
Last Reported Date: 06/17/15
Founded in 1984

dr. reddy's laboratories (DRRD) Top Compensated Officers

Co-Chairman, Chief Executive Officer, Managin...
Total Annual Compensation: 6.3M
Chairman of The Board, Member of The Manageme...
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2015.

dr. reddy's laboratories (DRRD) Key Developments

Dr. Reddy's Laboratories Ltd. Launches Generic Version of Parkinson's Drug in US

Dr. Reddy's Laboratories Ltd. announced the U.S. launch of Parkinson's treatment Pramipexole dihydrochloride extended release tablets, a generic form of Mirapex ER. The release in the U.S. follows the approval by the US Food and Drug Administration. The tablets are available in 0.375 mg, 0.75 mg, 3 mg and 4.5 mg in bottle count sizes of 30.

Dr. Reddy's Laboratories Ltd. Announces the Launch of PRAMIPEXOLE Dihydrochloride Extended Release Tablets

Dr. Reddy's Laboratories Ltd. announced that it has launched PRAMIPEXOLE dihydrochloride extended-release tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg, a therapeutic equivalent generic version of MIRAPEX ER (pramipexole dihydrochloride). Extended-Release Tablets in the US market on August 11, 2015, following the approval by the United States Food & Drug Administration (USFDA). The MIRAPEX ER® brand and generic had U.S. sales of approximately $48.3 Million MAT for the most recent twelve months ending in June 2015 according to IMS Health. Dr. Reddy's PRAMIPEXOLE dihydrochloride extended-release tablets mg are available in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count sizes of 30.

Dr. Reddy's Laboratories Ltd. Announces Strategic Collaboration with Amgen in India

Dr. Reddy’s Laboratories Ltd. announced that it has entered into a strategic collaboration with Amgen to market and distribute three Amgen medicines in India in the areas of oncology and cardiology. Under the terms of the collaboration, Dr. Reddy’s shall perform a full range of regulatory and commercial services to seek approval and launch Kyprolis (carfilzomib), BLINCYTO (blinatumomab) and Repatha (evolocumab) in India. The collaboration leverages the capabilities of both companies, combining three of Amgen’s innovative therapies with Dr. Reddy’s deep understanding of patient and physician needs in India.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
DRRD:IN 4,180.75 INR +50.65

DRRD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aurobindo Pharma Ltd 756.40 INR +11.05
Cadila Healthcare Ltd 1,929 INR +27.35
Croda International PLC 2,892 GBp +42.00
Sigma-Aldrich Corp $139.46 USD -0.19
Symrise AG €53.65 EUR +0.085
View Industry Companies
 

Industry Analysis

DRRD

Industry Average

Valuation DRRD Industry Range
Price/Earnings 29.1x
Price/Sales 4.4x
Price/Book 6.0x
Price/Cash Flow 29.0x
TEV/Sales 3.9x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact DR. REDDY'S LABORATORIES, please visit www.drreddys.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.